Balchem Corporation Earnings Recaps
Q3 2025
Oct 21, 2025
Balchem Corporation reported a strong third quarter in 2025, achieving record sales and profitability across all segments, marking the 25th consecutive quarter of year-over-year adjusted EBITDA growth.
Key takeaways
- Consolidated sales and adjusted EBITDA reached record levels, driven by robust demand in Human Nutrition and Health products.
- Year-over-year growth was noted in all three reporting segments: Human Nutrition, Animal Nutrition and Health, and Specialty Products.
- The company successfully managed to offset the impact of tariffs through strategic supply chain adjustments and pricing actions.
- Balchem's scientific research initiatives continue to advance, with significant findings from the NIH-funded choline biomarker study promising to enhance the understanding of human choline deficiencies.
- Ongoing investments in marketing capabilities, including the Real Science Exchange platform, are expanding brand reach and engagement within the industry.